MORRIS PLAINS, N.J., April 8, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that its patent application for “Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines” has been issued as U.S. patent no. 7,354,587. The allowed claims cover the use of antibodies reactive with CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, of immune cells to deliver cancer and infectious disease vaccines into immune cells. Claims of the patent also cover use of cytokines to enhance the response to the vaccine-antibody complex.
